JERUSALEM--(BUSINESS WIRE)--Sep. 24, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the
launch of the generic equivalent to ADENOSCAN® (adenosine injection) in
the United States. Teva was first to file, making the product eligible
for 180 days of marketing exclusivity.
ADENOSCAN® is supplied as 20 mL and 30 mL vials and is indicated as an
adjunct to thallium-201 myocardial perfusion scintigraphy in patients
unable to exercise adequately. Marketed by Astellas Pharma, ADENOSCAN®
had annual sales of approximately $65 million in the United States,
according to IMS data as of June 30, 2013.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,000 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $20.3 billion
in net revenues in 2012.
Teva's Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements are
based on management’s current beliefs and expectations and involve a
number of known and unknown risks and uncertainties that could cause our
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products, including
our ability to develop, manufacture, market and sell biopharmaceutical
products, competition for our innovative products, especially COPAXONE®
(including competition from innovative orally-administered alternatives,
as well as from potential purported generic equivalents), competition
for our generic products (including from other pharmaceutical companies
and as a result of increased governmental pricing pressures),
competition for our specialty pharmaceutical businesses, our ability to
achieve expected results through our specialty, including innovative,
R&D efforts, the effectiveness of our patents and other protections for
innovative products, decreasing opportunities to obtain U.S. market
exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions, the
effects of increased leverage as a result of recent acquisitions, the
extent to which any manufacturing or quality control problems damage our
reputation for high quality production and require costly remediation,
our potential exposure to product liability claims to the extent not
covered by insurance, increased government scrutiny in both the U.S. and
Europe of our agreements with brand companies, potential liability for
sales of generic products prior to a final resolution of outstanding
patent litigation, our exposure to currency fluctuations and
restrictions as well as credit risks, the effects of reforms in
healthcare regulation and pharmaceutical pricing and reimbursement, any
failures to comply with complex Medicare and Medicaid reporting and
payment obligations, governmental investigations into sales and
marketing practices (particularly for our specialty pharmaceutical
products), uncertainties surrounding the legislative and regulatory
pathways for the registration and approval of biotechnology based
products, adverse effects of political or economical instability,
corruption, major hostilities or acts of terrorism on our significant
worldwide operations, interruptions in our supply chain or problems with
our information technology systems that adversely affect our complex
manufacturing processes, any failure to retain key personnel or to
attract additional executive and managerial talent, the impact of
continuing consolidation of our distributors and customers, variations
in patent laws that may adversely affect our ability to manufacture our
products in the most efficient manner, potentially significant
impairments of intangible assets and goodwill, potential increases in
tax liabilities, the termination or expiration of governmental programs
or tax benefits, environmental risks and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2012 and in our other filings with the U.S. Securities and Exchange
Commission. Forward-looking statements speak only as of the date on
which they are made and the Company undertakes no obligation to update
or revise any forward looking statement, whether as a result of new
information, future events or otherwise.
Source: Teva Pharmaceutical Industries Ltd.